Search results for "Brimonidine Tartrate"

showing 3 items of 3 documents

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension

2014

Introduction Fixed-combination intraocular pressure (IOP)—lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) versus concomitant administration of brinzolamide 1% plus brimonidine 0.2% (BRINZ + BRIM) in patients with open-angle glaucoma or ocular hypertension. Methods This was a prospective, phase 3, multicenter, double-masked, 6-month trial. Patients who had insufficient IOP control with monotherapy or who were receiving 2 IOP-lowering medications were randomized 1:1 to receive twice-dail…

MaleIntraocular pressuremedicine.medical_specialtyConcomitantgenetic structuresIntraocular pressureBrinzolamideThiazinesOcular hypertensionGlaucomaOcular hypertensionlaw.inventionTonometry OcularRandomized controlled trialDouble-Blind MethodlawOphthalmologyQuinoxalinesConcomitant TherapyMedicineHumansPharmacology (medical)Fixed combinationCarbonic anhydrase inhibitorAntihypertensive AgentsOriginal ResearchAgedMedicine(all)Sulfonamidesbusiness.industryBrimonidineAlpha-2 agonistSimbrinza®GlaucomaGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesDysgeusiaOphthalmologyDrug CombinationsTreatment OutcomeBrimonidine TartrateFemalesense organsmedicine.symptombusinessGlaucoma Open-Anglemedicine.drugAdvances in Therapy
researchProduct

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.

2019

Purpose: To evaluate the additive intraocular pressure–lowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a prostaglandin analog (PGA) in patients with open-angle glaucoma or ocular hypertension insufficiently controlled with PGA monotherapy. Methods: In this Phase 4, double-masked trial, patients aged ⩾18 years, with a mean intraocular pressure of ⩾19 and <32 mm Hg in at least one eye were randomized (1:1) to receive BBFC + PGA ( n = 96) or vehicle + PGA ( n = 92) for 6 weeks. The primary endpoint was the mean change in diurnal intraocular pressure from baseline (averaged over 09:00 and 11:00 h) at Week 6. Results: The mean diu…

Malemedicine.medical_specialtyOpen angle glaucomagenetic structuresFixed-dose combinationBrinzolamideThiazinesOcular hypertensionopen-angle glaucoma03 medical and health sciencesTonometry Ocular0302 clinical medicineTravoprostDouble-Blind Methodintraocular pressure reductionOphthalmologyOriginal Research ArticlesmedicineAdrenergic alpha-2 Receptor AgonistsHumansCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureAgedAged 80 and overSulfonamidesbusiness.industryprostaglandin analogsBrimonidineBrinzolamide/brimonidine fixed-dose combinationGeneral MedicineMiddle Agedmedicine.diseaseAdjuncteye diseasesOphthalmologyDrug CombinationsProstaglandin analogBrimonidine Tartrate030221 ophthalmology & optometryLatanoprostocular hypertensionFemalesense organsbusiness030217 neurology & neurosurgeryGlaucoma Open-Anglemedicine.drugEuropean journal of ophthalmology
researchProduct

Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels.

2005

To evaluate the influence of dapiprazole versus brimonidine on pupil size at various illumination levels.Department of Ophthalmology, Johannes Gutenberg-University, Mainz, Germany.In randomized prospective study, 19 healthy volunteers received 2 ophthalmic solutions, dapiprazole and brimonidine, 1 in each eye, for intraindividual comparison. Before and after application, pupil diameter was measured using an infrared binocular pupillometer at 3 illumination levels (0.03, 0.82, and 6.4 lux).Only slight pupil dilation was observed under scotopic conditions after application of both agents. After 20 minutes, the median reduction in pupil width was 1.4 mm for brimonidine and 0.9 mm for dapiprazo…

medicine.medical_specialtygenetic structuresLightmedicine.medical_treatmentDark AdaptationDiagnostic Techniques OphthalmologicalPupilPiperazinesBrimonidine TartrateDapiprazoleRefractive surgeryOphthalmologyQuinoxalinesMydriasisPupillary responseMedicineHumansScotopic visionProspective StudiesAdrenergic alpha-Antagonistsbusiness.industryBrimonidinePupilTriazoleseye diseasesSensory SystemsOphthalmologyAnesthesiaBrimonidine TartrateSurgerysense organsmedicine.symptomOphthalmic SolutionsbusinessAdrenergic alpha-Agonistsmedicine.drugJournal of cataract and refractive surgery
researchProduct